Flow-mediated dilation

When blood flow through a large artery is increased, the extra flow and shear stress on the vessel wall lead the inner lining, the endothelium, to widen the artery, largely through nitric oxide [2]. FMD measures this response, so it is used as a noninvasive test of endothelial function [2]. A 2011 methods guideline noted that FMD had been in use for almost 20 years as a noninvasive way to examine how blood vessels dilate in living people [1].

In observational research, FMD is affected by cardiovascular risk factors, relates to the function of the arteries that supply the heart and independently predicts cardiovascular outcomes [2]. It is also used to examine the short- and long-term effects of physiological and drug interventions in humans [2], and it has been described as a surrogate marker of vascular health [1].

FMD is a surrogate marker. A trial that reports a change in FMD has measured a blood vessel response, not a clinical outcome.

Method details change the result. Studies have varied in the protocols applied, the methods of analysis and how results were interpreted, and those differences affect the size of the response, can lead to spurious interpretations and limit comparisons between studies [1]. Despite concerns about reproducibility, highly reliable measurements are possible when specialized laboratories follow standardized protocols, and a 2019 expert consensus set out updated guidelines for performing the test [2]. The authors expect more uniform methods to improve comparability between studies [2].

NootropicsWork reports FMD findings as findings on a vascular marker, with the population, the comparison and the timing of the measurement, and not as evidence about heart health outcomes.

Flavanols, randomized controlled trial.